盐酸氨非他酮,Bupropion hydrochloride ,超级纯,99.89%

产品编号:西域试剂-B0403A| CAS NO:31677-93-7| 分子式:C13H19Cl2NO| 分子量:276.20

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
西域试剂-B0403A
558.00 杭州 北京(现货)
西域试剂-B0403A
930.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

盐酸氨非他酮

产品介绍 Bupropion (Amfebutamone) hydrochloride 是一种口服有效,选择性的 5-羟色胺再摄取抑制剂 (SSRI)。Bupropion hydrochloride 阻断多巴胺 (DA) 摄取或 Methamphetamine 诱导的 DA 释放,IC50 分别为 1.76 μM 和 14.2 μM。Bupropion hydrochloride 是一种非典型氨基酮类抗抑郁剂,可用于辅助戒烟的研究。
生物活性

Bupropion (Amfebutamone) hydrochloride is an orally active, selective serotonin reuptake inhibitor (SSRI).Bupropion block dopamine (DA) uptake or Methamphetamine-induced DA release with IC50s of 1.76 μM and 14.2 μM, respectively. Bupropion hydrochloride is an atypical antidepressant of the aminoketone group. Bupropion hydrochloride can be used for the research of smoking cessation aid.

体外研究

Bupropion (Amfebutamone) hydrochloride inhibits CYP2D6 with the IC50 of 58 μM.
Bupropion hydrochloride, an atypical antidepressant, induces endoplasmic reticulum stress and caspase-dependent cytotoxicity in SH-SY5Y cells.
Bupropion hydrochloride activates caspase 3 through the induction of endoplasmic reticulum stress responses and activation of JNK, and consequently induces apoptotic cell death in SH-SY5Y cells.
Bupropion (1-100 µg/mL) hydrochloride reduces cell viability. Bupropion-induced reduction in cell viability may have been a consequence of apoptotic mechanisms.
Bupropion (100 μg/mL) hydrochloride increases the phosphorylated forms of EIF-2α, JNK, and p38 MAPK, and the expression of GRP78 within 1 h.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line: SH-SY5Y human catecholaminergic cells
Concentration: 0, 1, 10, 50, and 100 µg/mL
Incubation Time: 24 hours
Result: Cell viability decreased significantly in a concentration-dependent manner.

Western Blot Analysis

Cell Line: SH-SY5Y human catecholaminergic cells
Concentration: 100 μg/mL
Incubation Time: 1, 3, 8, 24 hours
Result: The immunoreactivity for p-EIF-2α increased significantly within 1 h of Bupropion treatment and was sustained for 3 h, indicating that Bupropion rapidly stimulates PERK.
Slightly but significantly increased the expression of GRP78 and markedly activated JNK. This early activation of the ER stress pathways by Bupropion returned to basal levels 8 h after treatment.
体内研究
(In Vivo)

Bupropion (Amfebutamone) hydrochloride shows convulsant and anticonvulsant effects in mice. Bupropion dose-dependently causes clonic convulsions in mice, with the CD50 (convulsive dose50, i.e., the dose producing convulsions in 50% of mice) at 119.7 mg/kg[4].
Bupropion (10, 15, 20 and 40 mg/kg., i.p.; Male albino mice weighing between 22–30 g) hydrochloride dose-dependently decreases immobility period (in seconds) with respect to vehicle control group. ED50 values of bupropion in reducing the immobility period was found to be 18.5 and 18 mg/kg i.p., in forced swim test and tail suspension test, respectively. Bupropion (10, 20 and 40 mg/kg., i.p.) hydrochloride dose-dependently increases the concentration of free dopamine and its metabolite homovanillic acid in the mouse brain[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Swiss mice weighing 20-25 g[4]
Dosage: 100-160 mg/kg
Administration: IP
Result: Caused clonic convulsions, with the CD50 and CD97 being 119.7 (104.1-137.6) and 156.7 mg/kg, respectively.
When given at a full convulsant dose of 160 mg/kg, the median latency was 6.00 min (3.50-8.15). Tonic convulsions were observed occasionally (1 per 8 mice) only in the groups receiving 140 or 160 mg/kg.
体内研究

Bupropion (Amfebutamone) hydrochloride shows convulsant and anticonvulsant effects in mice. Bupropion dose-dependently causes clonic convulsions in mice, with the CD50 (convulsive dose50, i.e., the dose producing convulsions in 50% of mice) at 119.7 mg/kg[4].
Bupropion (10, 15, 20 and 40 mg/kg., i.p.; Male albino mice weighing between 22–30 g) hydrochloride dose-dependently decreases immobility period (in seconds) with respect to vehicle control group. ED50 values of bupropion in reducing the immobility period was found to be 18.5 and 18 mg/kg i.p., in forced swim test and tail suspension test, respectively. Bupropion (10, 20 and 40 mg/kg., i.p.) hydrochloride dose-dependently increases the concentration of free dopamine and its metabolite homovanillic acid in the mouse brain[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Swiss mice weighing 20-25 g[4]
Dosage: 100-160 mg/kg
Administration: IP
Result: Caused clonic convulsions, with the CD50 and CD97 being 119.7 (104.1-137.6) and 156.7 mg/kg, respectively.
When given at a full convulsant dose of 160 mg/kg, the median latency was 6.00 min (3.50-8.15). Tonic convulsions were observed occasionally (1 per 8 mice) only in the groups receiving 140 or 160 mg/kg.
体内研究

Bupropion (Amfebutamone) hydrochloride shows convulsant and anticonvulsant effects in mice. Bupropion dose-dependently causes clonic convulsions in mice, with the CD50 (convulsive dose50, i.e., the dose producing convulsions in 50% of mice) at 119.7 mg/kg[4].
Bupropion (10, 15, 20 and 40 mg/kg., i.p.; Male albino mice weighing between 22–30 g) hydrochloride dose-dependently decreases immobility period (in seconds) with respect to vehicle control group. ED50 values of bupropion in reducing the immobility period was found to be 18.5 and 18 mg/kg i.p., in forced swim test and tail suspension test, respectively. Bupropion (10, 20 and 40 mg/kg., i.p.) hydrochloride dose-dependently increases the concentration of free dopamine and its metabolite homovanillic acid in the mouse brain[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Swiss mice weighing 20-25 g[4]
Dosage: 100-160 mg/kg
Administration: IP
Result: Caused clonic convulsions, with the CD50 and CD97 being 119.7 (104.1-137.6) and 156.7 mg/kg, respectively.
When given at a full convulsant dose of 160 mg/kg, the median latency was 6.00 min (3.50-8.15). Tonic convulsions were observed occasionally (1 per 8 mice) only in the groups receiving 140 or 160 mg/kg.
性状Solid
溶解性数据
In Vitro: 

DMSO : 33.33 mg/mL (120.67 mM; ultrasonic and warming and heat to 80°C)

H2O : 5.56 mg/mL (20.13 mM; ultrasonic and warming and heat to 80°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.6206 mL 18.1028 mL 36.2056 mL
5 mM 0.7241 mL 3.6206 mL 7.2411 mL
10 mM 0.3621 mL 1.8103 mL 3.6206 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (9.05 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (9.05 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液
  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (9.05 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (9.05 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (9.05 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (9.05 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 西域 网站选购。
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


符号 GHS02 GHS06 GHS08
GHS02, GHS06, GHS08
信号词 Danger
危害声明 H225-H301 + H311 + H331-H370
警示性声明 P210-P260-P280-P301 + P310-P311
个人防护装备 dust mask type N95 (US);Eyeshields;Faceshields;Gloves
危害码 (欧洲) Xn,Xi
风险声明 (欧洲) R22:Harmful if swallowed.
安全声明 (欧洲) S36
危险品运输编码 UN1230 - class 3 - PG 2 - Methanol, solution
WGK德国 3
RTECS号 UG8858000
海关编码 2922399090
闪点(华氏) 48.2 °F
闪点(摄氏) 9 °C
1. 物质的识别
产品名: Amfebutamone hydrochloride
CAS号: 31677-93-7
制造商/供应商: 西域试剂
网站:www.hzbp.cn   邮件:13911702513@139.com
2. 合成/成分数据
产品名: Amfebutamone hydrochloride
别名: Bupropion hydrochloride
分子式: C13H18ClNO.HCl
分子量: 276.2
3. 急救措施
吸入后: 如果吸入,移至空气新鲜处,如果呼吸困难,给输氧,如呼吸停止,给予人工呼吸。
皮肤接触后: 用大量的水冲洗,移除污染的衣服和鞋子。
眼睛接触后: 检查并取下隐形眼镜,并用大量的水冲洗;呼叫医生。
吞食后: 如果吞食,用大量纯净水漱口;呼叫医生。
4. 消防措施
适当的灭火剂: 雾状水,二氧化碳,干粉或泡沫。
防护设备: 穿戴自给式呼吸器和防护服,以防止与皮肤和眼睛接触。
5. 泄漏应急处理
安全防范措施: 封锁泄漏区域;穿戴自给式呼吸器,防护服和厚橡胶手套。
清洁/收集措施: 使用液体粘合原料(硅藻土,通用粘合剂)吸取精细粉末;
使用酒精擦洗表面和设备除去污渍;
根据第11条处理被污染的材料。
6. 处理和储存
安全处理说明: 避免吸入和接触皮肤,眼睛及衣物;材料可能略微具有刺激性。
储存: 粉末型式       -20°C   3年;4°C   2年
溶于溶剂       -80°C   6个月;-20°C   1个月
7. 接触控制和个人防护
呼吸设备: NIOSH / MSHA认可的呼吸器。
双手保护: 耐化学腐蚀的橡胶手套。
眼睛防护: 化学安全护目镜。
8. 稳定性和反应活性
稳定性: 按照说明存储是稳定的;避免强氧化剂。
热分解/其他要避免的情况: 避免光和热。
9. 毒性资料
急性毒性: 无可用资料。
主要刺激性影响: 无可用资料。
在皮肤上: 无可用资料。
对眼睛: 无可用资料;可能具有刺激性。
10. 生态资料
一般注意事项: 无可用资料。
11. 废弃处置
按照所在国家,省份,县市和地方的法规处置。
12. 运输信息
正确的运输名称:
非危险品运输: 这种物质被视为非危险品运输。
13. 法规信息
尚未有针对此产品作出的化学安全性评估。
14. 其他信息
这种化学品仅供受过训练的,有经验的研究人员在穿戴适当装备和授权允许的情况下进行操作处理。以上信息基于我们目前的知识被认为是正确的,但只适用于作为有经验人员的指导。请咨询您自己的安全顾问,并遵守当地和国家的安全法规。在任何其他没有被警告的情况下,并不意味着绝对没有危险存在。西域生物技术不承担任何使用这种化学品所造成的损害和责任。2023 西域生物技术版权所有。





服务热线

13911702513
18601927057

微信客服